Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
The impact of microbial genomics on the development of new antibiotics has been surprisingly minimal to date. Although many potential targets for novel antimicrobials have been identified through genomics, the identification of inhibitory molecules that also possess drug-like properties has been a severe challenge. This feature will discuss several possible confounding issues and solution paths in the search for new antibiotics that are active against the threat of drug-resistant pathogens.
Dougherty
Thomas J
TJ
Pfizer Global Research and Development, Infectious Diseases Research, Eastern Point Road, Groton, CT 06340, USA. Thomas.J.Dougherty@Pfizer.com
Miller
Paul F
PF
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism*; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism; D016680:Genome, Bacterial; D023281:Genomics / Q000379:methods; D015394:Molecular Structure; D011485:Protein Binding
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004791:Enzyme Inhibitors